Innate Pharma S.A. (IPHA)
NASDAQ·Healthcare·Biotechnology
$1.77
+1.14%
Mkt Cap $150.90M
Analyst Ratings
No recent rating data.
Price Target (2 analysts)
$3.50
Range $2.00 – $5.00
Implied Upside
+97.7%
Consensus $3.50 vs current $1.77
NASDAQ·Healthcare·Biotechnology
$1.77
+1.14%
Mkt Cap $150.90M
No recent rating data.
Price Target (2 analysts)
$3.50
Range $2.00 – $5.00
+97.7%
Consensus $3.50 vs current $1.77